Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 454
6
Diseases
39
Unique genes
0.204
Avg. similarity score
Cryptogenic multifocal ulcerous stenosing enteritis
Most-connected disease (4 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Cryptogenic multifocal ulcerous stenosing enteritis
Cytosolic phospholipase-a2 alpha deficiency associated bleeding disorder
Gastrointestinal ulceration, recurrent, with dysfunctional platelets
Schizoaffective disorder
Curling ulcer
Neurodevelopmental disorder with seizures
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Cryptogenic multifocal ulcerous stenosing enteritis | 4 | 4 | 1 |
| Cytosolic phospholipase-a2 alpha deficiency associated bleeding disorder | 4 | 4 | 1 |
| Gastrointestinal ulceration, recurrent, with dysfunctional platelets | 4 | 4 | 1 |
| Schizoaffective disorder | 4 | 4 | 34 |
| Curling ulcer | 3 | 3 | 6 |
| Neurodevelopmental disorder with seizures | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| PLA2G4A | 5 / 6 | Cryptogenic multifocal ulcerous stenosing enteritis, Curling ulcer, Cytosolic phospholipase-a2 alpha deficiency associated bleeding disorder, Gastrointestinal ulceration, recurrent, with dysfunctional platelets and 1 more |
| GABRA4 | 2 / 6 | Neurodevelopmental disorder with seizures, Schizoaffective disorder |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Retrograde endocannabinoid signaling | KEGG | 5 / 149 | 10.3× | 1.13e-4 | 2.09e-3 ✓ sig. |
| Nicotine addiction | KEGG | 3 / 41 | 22.5× | 3.10e-4 | 4.62e-3 ✓ sig. |
| Serotonergic synapse | KEGG | 4 / 115 | 10.7× | 5.07e-4 | 6.74e-3 ✓ sig. |
| VEGF signaling pathway | KEGG | 3 / 60 | 15.4× | 9.53e-4 | 1.09e-2 ✓ sig. |
| Long-term depression | KEGG | 3 / 60 | 15.4× | 9.53e-4 | 1.09e-2 ✓ sig. |
| GABA receptor activation | Reactome | 2 / 16 | 38.5× | 1.20e-3 | 1.30e-2 ✓ sig. |
| Syndecan interactions | Reactome | 2 / 16 | 38.5× | 1.20e-3 | 1.30e-2 ✓ sig. |
| Trafficking of GluR2-containing AMPA receptors | Reactome | 2 / 17 | 36.2× | 1.36e-3 | 1.43e-2 ✓ sig. |
| Pathways in cancer | KEGG | 7 / 533 | 4.0× | 1.45e-3 | 1.50e-2 ✓ sig. |
| Efferocytosis | KEGG | 4 / 157 | 7.8× | 1.62e-3 | 1.63e-2 ✓ sig. |
| Leishmaniasis | KEGG | 3 / 78 | 11.8× | 2.04e-3 | 1.93e-2 ✓ sig. |
| GABAergic synapse | KEGG | 3 / 89 | 10.4× | 2.96e-3 | 2.53e-2 ✓ sig. |
| Morphine addiction | KEGG | 3 / 91 | 10.2× | 3.16e-3 | 2.64e-2 ✓ sig. |
| Biosynthesis of EPA-derived SPMs | Reactome | 1 / 1 | 308× | 3.25e-3 | 2.70e-2 ✓ sig. |
| Biosynthesis of DPAn-3 SPMs | Reactome | 1 / 1 | 308× | 3.25e-3 | 2.70e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| response to xenobiotic stimulus | GO:0009410 | 7 / 248 | 13.5× | 7.13e-7 | 6.53e-5 ✓ sig. |
| response to estradiol | GO:0032355 | 5 / 84 | 28.5× | 8.31e-7 | 7.37e-5 ✓ sig. |
| regulation of cell population proliferation | GO:0042127 | 6 / 201 | 14.3× | 3.49e-6 | 2.37e-4 ✓ sig. |
| positive regulation of exit from mitosis | GO:0031536 | 2 / 4 | 240× | 2.54e-5 | 1.10e-3 ✓ sig. |
| prostaglandin secretion | GO:0032310 | 2 / 5 | 192× | 4.23e-5 | 1.62e-3 ✓ sig. |
| mammary gland development | GO:0030879 | 3 / 37 | 38.9× | 6.22e-5 | 2.18e-3 ✓ sig. |
| conditioned place preference | GO:1990708 | 2 / 6 | 160× | 6.33e-5 | 2.21e-3 ✓ sig. |
| mammary gland duct morphogenesis | GO:0060603 | 2 / 8 | 120× | 1.18e-4 | 3.48e-3 ✓ sig. |
| negative regulation of glial cell apoptotic process | GO:0034351 | 2 / 9 | 106× | 1.51e-4 | 4.17e-3 ✓ sig. |
| positive regulation of smooth muscle cell proliferation | GO:0048661 | 3 / 52 | 27.6× | 1.73e-4 | 4.58e-3 ✓ sig. |
| regulation of postsynaptic membrane potential | GO:0060078 | 3 / 59 | 24.4× | 2.52e-4 | 5.98e-3 ✓ sig. |
| angiogenesis | GO:0001525 | 5 / 284 | 8.4× | 2.95e-4 | 6.70e-3 ✓ sig. |
| retina vasculature development in camera-type eye | GO:0061298 | 2 / 15 | 63.9× | 4.38e-4 | 8.68e-3 ✓ sig. |
| hyaluronan catabolic process | GO:0030214 | 2 / 16 | 59.9× | 5.00e-4 | 9.48e-3 ✓ sig. |
| prostaglandin biosynthetic process | GO:0001516 | 2 / 17 | 56.4× | 5.66e-4 | 1.03e-2 ✓ sig. |